NRSN Neurosense Therapeutics Ltd
Company Analysis
Latest News
🔴 Neurosense Therapeutics is trading 11.36% down today amid broader biotech weakness and Nasdaq compliance concerns
Neurosense Therapeutics is trading 11.36% down today at $0.49, extending a multi-day slide despite a lack of fresh company-specific catalysts. • The downward...
🔴 Neurosense Therapeutics is trading 11.3% down today with no fresh news catalyst
Neurosense Therapeutics is trading 11.3% down today at $0.52 as the stock extends its decline without a fresh news catalyst. * The move comes with no new...
🔴 Neurosense Therapeutics is trading 13% down today, extending a week-long slide on no fresh news
Neurosense Therapeutics is trading 13% down at $0.51 in pre-market, extending a steady slide from $0.70 on July 21. • The stock has seen a consistent decline...
🔴 Neurosense Therapeutics is trading 8% down today amid intraday volatility
Neurosense Therapeutics is trading at $0.60 (-7.68%) today amid intraday volatility, as no new company-specific catalysts have been identified to explain the...
NeuroSense Eyes Canadian Approval for Its ALS Drug — But Can a $25 Million Company Actually Bring It to Market?
Shares of NeuroSense Therapeutics shifted sharply higher on July 24, climbing 10.5% to $0.72, after the company announced it will file for Canadian approval of...
🟢 Neurosense Therapeutics is trading 10.5% up today on plans to file Health Canada submission for ALS drug PrimeC
Neurosense Therapeutics is trading at $0.72 (10.5% up) following its announcement to file a New Drug Submission with Health Canada for its ALS therapy,...
NeuroSense to seek Canadian PrimeC approval, citing long-term survival benefit
NeuroSense Therapeutics announced plans on July 22, 2026, to file a New Drug Submission (NDS) with Health Canada for PrimeC. The company expects to complete...
🔴 Neurosense Therapeutics is trading 13.5% down
Neurosense Therapeutics is trading at $0.59, down 13.5% from a comparison close of $0.68 during regular trading. This is a price-action follow-up, so a...
NeuroSense Advances ALS Drug PrimeC, Reducing Protein Linked to 97% of Cases
NeuroSense Therapeutics (NASDAQ: NRSN) met the primary efficacy endpoint in its Phase 2b PARADIGM trial. The study evaluated the ALS drug candidate PrimeC....
🔴 NRSN is trading 5.5% down today after meeting Phase 2b ALS study endpoint
NRSN is trading 5.5% down now at $0.72 after announcing it achieved the primary endpoint in its Phase 2b ALS study, a key milestone for its lead asset...
NeuroSense's Sub-Dollar Stock Gets a Jolt From Alzheimer's Data and Insider Cash — But Can an Eight-Patient Study Justify Real Conviction?
Shares shifted as NeuroSense Therapeutics (NRSN) ticked up 3% to $0.78 ahead of its June 30 Q1 earnings report, capping a string of catalysts: fresh...
🟢 NRSN is trading 3% up today ahead of Q1 earnings and positive clinical updates
NRSN is trading 3% up at $0.78 as investors position ahead of its June 30, 2026, Q1 earnings report and react to positive clinical and financing updates. •...
NeuroSense Therapeutics Ltd Q1 2026 Earnings Preview: What Analysts Expect on June 30, 2026
Analysts expect NeuroSense Therapeutics to report a quarterly loss of $0.14 per share on zero revenue, with the current stock price of $1.42 trailing...
🟢 NRSN up 1.58% today on positive PrimeC Alzheimer's biomarker findings
• NeuroSense Therapeutics (NRSN) is trading up 1.58% today at $0.77 following the announcement of positive biomarker findings from its Phase 2 study of PrimeC...
🟢 Neurosense Therapeutics Ltd is trading 5.6% up today ahead of Q1'26 earnings report
• Neurosense Therapeutics Ltd is trading 5.6% up at $0.85 in pre-market, extending a sharp rebound from recent lows. • The company is expected to announce its...
🟢 Neurosense Therapeutics Ltd is trading 5.7% up today after notable insider buying by top executives
Neurosense Therapeutics Ltd is trading 5.7% up today at $0.74 following significant insider buying by the company's top leadership. • On June 16, 2026, the...
🟢 Neurosense Therapeutics Ltd is trading 5.7% up today amid insider buying by CEO and CFO
• NeuroSense Therapeutics Ltd is trading at $0.74, up 5.7% in pre-market sessions, potentially driven by recent insider buying. • On June 16, 2026, CEO Alon...
🟢 Neurosense Therapeutics Ltd makes sharp 12.1% jump
NRSN is trading at $0.79, up 12.1% versus the comparison close of $0.70 during after-hours. This is a price-movement alert; no separate company-specific...
🟢 Neurosense Therapeutics Ltd. (NRSN) Surges 10% on Insider Buying by CEO and CFO
Neurosense Therapeutics Ltd. (NRSN) traded at $0.77 in after-hours, marking a 10% increase from its regular session close of $0.70. This significant movement...
🔴 Neurosense Therapeutics Ltd is trading 6.2% down today amid low-float volatility and no clear catalyst
Neurosense Therapeutics Ltd is trading 6.2% down at $0.69, extending a choppy micro-cap biotech trend despite a broader market rally. • The move appears...